From the Journals

Therapeutic drug monitoring has little value during infliximab induction


NEW YORK (Reuters Health) – Results of a randomized, controlled trial do not support routine use of proactive therapeutic drug monitoring (TDM) during infliximab induction for improving disease remission rates in patients with rheumatoid arthritis and other chronic immune-mediated inflammatory diseases.

Proactive TDM tailors biologic therapy to individual patients by measuring serum drug levels and antidrug antibodies (ADAs) and adjusts treatment doses based on the levels, with the goal of maximizing efficacy and safety of biologic drugs.

Proactive TDM has been adopted by some clinicians but whether it improves clinical outcomes when implemented at the time of drug initiation, compared with standard therapy, remains unclear.

To investigate, researchers with the Norwegian Drug Monitoring (NOR-DRUM) trial enrolled 411 patients with RA, psoriatic arthritis, axial spondyloarthritis, psoriasis, or inflammatory bowel disease who were initiating infliximab.

Patients were randomly allocated to proactive TDM or standard care without TDM. The results are based on 398 patients – 198 in the TDM group and 200 in the standard-care group.

The primary endpoint of clinical remission was achieved in 100 (51%) patients in the TDM group and in 106 (53%) patients in the standard-care group, with no significant difference between group (adjusted difference, 1.5%; 95% confidence interval, –8.2% to 11.1%), Dr. Silje Watterdal Syversen of Diakonhjemmet Hospital in Oslo and colleagues reported in JAMA.

Adverse events were reported in 135 patients (68%) in the TDM group and 139 patients (70%) in the standard therapy group. Eight percent of patients on standard therapy had an infusion-related reaction versus 3% of the TDM group.

The researchers cautioned that the trial was open label and bias because of lack of double blinding is possible. Also the trial did not have statistical power to test hypotheses within each disease subgroup and minimum clinically important differences were not available for all outcomes.

The authors of a linked editorial noted that, while this trial “convincingly demonstrated that in a mixed disease indication population, implementing TDM at time of initial induction therapy provided little benefit, it does not rule out potential benefit for patients at high risk for developing ADAs.”

“Patients with RA, those not receiving concomitant immunosuppression, those who developed ADAs against other (noninfliximab) monoclonal antibodies, and those with a loss of response (i.e., ‘reactive’ TDM on a case-specific basis, rather than ‘proactive’ TDM in everyone), might still benefit from TDM,” wrote Dr. Jeffrey Curtis of the University of Alabama at Birmingham and coauthors.

This study focused on induction therapy and assessed clinical remission at 30 weeks, they added, “but it is also important to determine whether TDM might improve durability of treatment effects by maintaining adequate drug levels and preventing ADA formation.”

“Patients with lower drug concentration levels are more likely to develop ADAs. Results might differ in a randomized trial examining the maintenance phase of infliximab treatment rather than induction, especially in less adherent patients who may miss doses, thereby facilitating immunogenicity,” Dr. Curtis and coauthors pointed out.

The study was funded by grants from the Norwegian Regional Health Authorities and the South-Eastern Norway Regional Health Authorities. The sponsor of the study was Diakonhjemmet Hospital.

SOURCE: and, JAMA, online May 4, 2021.

Reuters Health Information © 2021

Next Article: